CART-45

CART-45 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD45 (Receptor-type tyrosine-protein phosphatase C), a pan-hematopoietic antigen expressed on nearly all white blood cells and most hematologic malignancies. Developed by the University of Pennsylvania, this therapy is administered in combination with CD45 base-edited hematopoietic stem and progenitor cells (CD45BE-HSPCs). The approach utilizes CRISPR-base editing to modify the CD45 epitope on both the CAR T cells and the transplanted HSPCs, rendering them invisible to the CAR T cells. This prevents CAR T-cell fratricide and protects the patient's healthy blood-forming system from depletion, while allowing the CAR T cells to selectively target and eliminate malignant cells expressing the native CD45 protein. It is currently being evaluated in Phase 1 clinical trials for relapsed or refractory hematologic malignancies, including B-cell and T-cell non-Hodgkin lymphomas, Hodgkin lymphoma, and Richter's transformation.

Other names

autologous anti-CD45 CAR T cellsCD45BE-HSPCCD-45BE-HSPCCD 45BE-HSPC